Tagged with PDC-CRO

MEA For decades, the Middle East has faced a disproportionately high burden of rare genetic disorders, fuelled both by deep-rooted cultural practices and an overreliance on Western genomic data. Fast forward to 2026, and massive genome projects across the Gulf region are attempting to shift the narrative. Backed by immense sovereign…

UAE Dr Rania Alshami reflects on two decades in the Middle East and North Africa clinical research ecosystem, charting the region’s regulatory maturation, rare disease opportunities, and growing role in early-phase trials. She discusses patient access, genomics integration, sponsor engagement, and why MENA is emerging as a credible hub for innovation…

Saudi Arabia As a part of the sweeping transformation Saudi Arabia is achieving thanks to its Vision 2030, the Kingdom is also advancing its research ambitions. With the restructuring of its regulatory framework along with its well-established network of research institutes and bolstered by the integration of electronic health records, Saudi has…

Saudi Arabia Mohamed Mostafa explains how PDC-CRO’s successful 2023 was driven by a direct-to-biotech strategy, with the company now well-established as a comprehensive partner for biotech firms across the Gulf and Levant regions. Mostafa also outlines why Saudi Arabia is a key market for PDC-CRO, especially with recent healthcare sector developments and…

UAE Only a small percentage of global clinical research takes place in the Middle East and Africa region today. This means that full-service MEA-focused clinical research organisation PDC CRO has a wealth of untapped opportunities to develop, according to the company’s CEO Mohamed Mostafa. He outlines PDC’s important work on COVID-19…